Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.62 |
| ▸ | CTSS | P25774 | 5/20 | 0.62 |
| ▸ | CTSK | P43235 | 5/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7164779 | 1.00 | CTSL (0.62) | CTSLCTSSCTSKSIRT2SIRT1 | |
| SCHEMBL7785794 | 0.92 | CTSS (0.55) | CTSLCTSSCTSKCTSBATM | |
| SCHEMBL7286548 | 0.89 | CTSL (0.62) | CTSLCTSSCTSKCTSB | |
| SCHEMBL7286541 | 0.89 | CTSL (0.62) | CTSLCTSSCTSKCTSB | |
| SCHEMBL16847596 | 0.88 | CTSL (0.61) | CTSLCTSSCTSKSIRT2SIRT1 | |
| SCHEMBL16357709 | 0.88 | CTSS (0.67) | CTSLCTSSCTSKCTSB | |
| SCHEMBL11311383 | 0.87 | CTRB1 (0.48) | CTSLCTSSCTSKCTSBATM | |
| SCHEMBL4256367 | 0.86 | CTSS (0.55) | CTSLCTSSCTSKCTSBATM | |
| SCHEMBL7361628 | 0.86 | ITGB3 (0.52) | CTSLCTSSSIRT2SIRT1ECE1 | |
| SCHEMBL7361631 | 0.86 | ITGB3 (0.52) | CTSLCTSSSIRT2SIRT1ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | ENDOTIS PHARMA (FR) | 2010-04-01 | — | — | US | claimed |
| EP-2074131-A2 | ANTICOAGULANT COMPOUNDS | Endotis Pharma (FR) | 2009-07-01 | — | — | EP | claimed |
| WO-2008041131-A2 | ANTICOAGULANT COMPOUNDS | ENDOTIS PHARMA (FR) | 2008-04-10 | — | — | WO | claimed |
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | ENDOTIS PHARMA (FR) | 2010-04-01 | — | — | US | disclosed |
| EP-2074131-A2 | ANTICOAGULANT COMPOUNDS | Endotis Pharma (FR) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008041131-A2 | ANTICOAGULANT COMPOUNDS | ENDOTIS PHARMA (FR) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | SERPINC1, F2, FUT5 | CTSL 312/4885CTSS 595/4885CTSK 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.